Sentence examples for mutations between primary from inspiring English sources

We compared the intratumor heterogeneity of the three gene mutations between primary and metastatic tumors for each case.

There was no significant difference in the frequency of FGFR3 mutations between primary tumors (2%) and metastatic tumors (9%) (Table 3) (P = 0.1).

Both cases of D473 and DD59 underwent TACE before metastases were detected, which may cause point mutations [ 13], consistent with that percentages of common point mutations between primary tumor and metastasis are low for these two cases.

Exome analysis also revealed little difference in coding region point mutations between primary tumors and paired orthoxenografts, with a mean of 10 mutations in xenografts that were not present in the primary tumor.

Differences in the spectrum of mutations between primary atherosclerotic lesions, lipofibrous plaques, and total atherosclerotic lesions lie in the fact that, for the first two types, antiatherogenic mutation A1555G is representative.

Based on a hypothesis that the heterogeneity of KRAS mutations between primary and metastatic tumors may be responsible for this discrepancy, Italiano et al. analyzed 95 pairs of primary and metastatic tumors.

(B ) Change of VAF of mtDNA somatic mutation between primary and metastatic (or late) cancer tissues.

In previous studies, conservation of TP53 mutation between primary and paired CNS metastasis was reported (Piccirilli et al, 1994).

Recently, Dupont Jensen [ 55] et al showed that there is a discrepancy of PIK3CA mutation between primary and metastatic tumors, urging on a simultaneous detection of the two matched samples.

Blinded analysis of mutations from patients with multiple samples shows the ability of MiSeq TSACP to detect mutations reproducibly between primary tumour, synchronous metastases, and metachronous metastases (Table 2; patients 1 5 and 7).

Case #1 shows the same KRAS and TP53 mutations between the primary tumor and the recurrence, and case #6 has the same KRAS G12R mutation in the primary and in both metachronous pancreatic ductal adenocarcinomas.